NCT06914505

Brief Summary

The goal of this clinical trial is to learn if visual restoration therapy (VRT) (a type of treatment that aims to improve vision) works to the visual rehabilitation of patients with visual field defects. It will also learn about the safety of VRT. The main questions it aims to answer are:

  • Can visual reconstruction therapy help expand the visual field in patients with visual field defects?
  • What medical problems do patients with visual field defects experience during the procedure of VRT? Researchers will look at how patients with visual field defects who use a visual aid in combination with VRT and those who use a visual aid only, compare the visual field expansion at three months to see how well visual reconstruction therapy works. Participants will:
  • will undergo a specialized visual function assessment and be provided with a pair of appropriate vision aids.
  • Visit the clinic at one month and three months after enrolment for review of visual function and completion of a Chinese-version Low Vision Quality of Life (CLVQOL) questionnaire.
  • Participants receiving VRT will additionally undergo 30 minutes of VRT three times per week for 3 months.
  • Keep a diary for their symptoms and severity and frequency of occurrence during treatment.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
58

participants targeted

Target at P25-P50 for not_applicable

Timeline
20mo left

Started Apr 2025

Typical duration for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress39%
Apr 2025Dec 2027

First Submitted

Initial submission to the registry

March 30, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 6, 2025

Completed
9 days until next milestone

Study Start

First participant enrolled

April 15, 2025

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2027

Last Updated

April 6, 2025

Status Verified

March 1, 2025

Enrollment Period

2.7 years

First QC Date

March 30, 2025

Last Update Submit

April 4, 2025

Conditions

Keywords

visual field defectvisual restoration therapy

Outcome Measures

Primary Outcomes (1)

  • visual field mean deviation (MD) value

    using the Humphrey Field Analyzer 30-2 test to obtain MD values

    A total of 3 examinations were performed during the trial: before treatment, after 1 month of treatment, and after 3 months of treatment.

Study Arms (2)

VRT treatment group

EXPERIMENTAL

The participants will be provided with a pair of appropriate vision aids and will undergo 3 times 30-minute visual restoration therapy (VRT) training per week for three months.

Behavioral: visual restoration therapy

control group

NO INTERVENTION

Participants will be provided with a pair of appropriate vision aids, however without any visual treatment.

Interventions

In this study, we used a reversing checkerboard pattern as a stimulus and acted on the relatively dark spots area of the patient's visual field.

Also known as: photostimulation therapy
VRT treatment group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participants with a clear diagnosis of visual field defects.
  • Participants were between 18 and 80 years of age (including borderline values);
  • Participants have been treated for their primary disease and conditions are stable;
  • Participants are not at significant risk of vision loss in the last three months;
  • Participants do not have planned intraocular surgery during the trial period;
  • Participants can understand the trial protocol and sign informed consent.

You may not qualify if:

  • Participants diagnosed as blindness;
  • Participants with a previous history of seizures or other psychiatric disorders;
  • Participants with cognitive impairments;
  • Participant's attention span is less than 30 minutes;
  • Participants had conditions such as significant ptosis or severe dry eye;
  • Participants who were in poor general health or who could not cooperate in completing the study protocol for some reasons such as transport.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Zhen Li, MD. and PHD.

    Ophthalmology Department, Xuanwu Hospital,Capital Medical University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Zhen Li, MD. and PHD.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 30, 2025

First Posted

April 6, 2025

Study Start

April 15, 2025

Primary Completion (Estimated)

December 30, 2027

Study Completion (Estimated)

December 30, 2027

Last Updated

April 6, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share